In 2011, the first efficient response against MET-amplified lung cancer using a tyrosine kinase inhibitor (crizotinib) was reported in women harboring a high-level MET amplification, determined by FISH (MET/CEN7 ratio > 5) [17]. This evidence concerns the gene MET and lung carcinoma.